SEC Company Response from NORTHWEST BIOTHERAPEUTICS INC (NWBO) (CIK 0001072379) (NWBO) — Dec 1, 2014
NORTHWEST BIOTHERAPEUTICS INC (NWBO) (CIK 0001072379)
Date: Dec. 1, 2014 · CIK: 0001072379 · Accession: 0001144204-14-071665
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-35737
Letter
December 2, 2014
VIA EDGAR
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attn: Mr. Jeffrey P. Riedler, Assistant Director
Ms. Christina De Rosa
Mr. Daniel Greenspan
Re: Northwest Biotherapeutics, Inc.
Form 10-K for the Year Ended December 31, 2013
Filed April 1, 2014
File No. 001-35737
Ladies and Gentlemen:
On behalf of Northwest Biotherapeutics, Inc. (the “Company”), this letter responds to your letter, dated November 13, 2014 (the “Comment Letter”), regarding the above-referenced Annual Report on Form 10-K (the “Annual Report”), filed on April 1, 2014. We are working with Cognate BioServices, Inc. to respond to the Comment Letter, but require additional time. Accordingly, we are requesting until Friday, December 12, 2014 to allow additional time to compile our response.
If the Staff wishes to discuss this matter at any time, please do not hesitate to contact Linda Powers, President and Chief Executive Officer, or Leslie Goldman, Senior Vice President, Business Development at (240) 497-9024.
Very truly yours,
/s/ Linda F. Powers
Show Raw Text
CORRESP
1
filename1.htm
December 2, 2014
VIA EDGAR
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attn: Mr. Jeffrey P. Riedler, Assistant Director
Ms. Christina De Rosa
Mr. Daniel Greenspan
Re: Northwest Biotherapeutics, Inc.
Form 10-K for the Year Ended December 31, 2013
Filed April 1, 2014
File No. 001-35737
Ladies and Gentlemen:
On behalf of Northwest Biotherapeutics,
Inc. (the “Company”), this letter responds to your letter, dated November 13, 2014 (the “Comment Letter”),
regarding the above-referenced Annual Report on Form 10-K (the “Annual Report”), filed on April 1, 2014. We
are working with Cognate BioServices, Inc. to respond to the Comment Letter, but require additional time. Accordingly, we are requesting
until Friday, December 12, 2014 to allow additional time to compile our response.
If the Staff wishes to discuss this matter
at any time, please do not hesitate to contact Linda Powers, President and Chief Executive Officer, or Leslie Goldman, Senior Vice
President, Business Development at (240) 497-9024.
Very truly yours,
/s/ Linda F. Powers
Linda F. Powers
President and Chief Executive Officer
cc: Glenn R. Pollner, Gibson, Dunn & Crutcher LLP
Reed Brodsky, Gibson, Dunn & Crutcher LLP
William Scherman, Gibson, Dunn & Crutcher LLP